Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.

Tan B, Pan XH, Chew HSJ, Goh RSJ, Lin C, Anand VV, Lee ECZ, Chan KE, Kong G, Ong CEY, Chung HC, Young DY and 8 more

Show all authors

Chan MY, Khoo CM, Mehta A, Muthiah MD, Noureddin M, Ng CH, Chew NWS, Chin YH

International journal of obesity (2005)31 May 2023Cited by 58 (Europe PMC)

PMID37253796DOI10.1038/s41366-023-01321-5PepBankPUB-37253796

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with overweight or obesity, a pooled single-arm analysis of tirzepatide trials found that 78.22% achieved weight loss of 5% or more.
In plain wordsIn pooled trials in people with overweight or obesity, 78.22% on tirzepatide lost at least 5% of body weight.
Peptide
Tirzepatide
Outcome
Not applicableProportion achieving at least 5% weight loss
Study
n = 5,800
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Proportion with 5% or more weight loss
78.22%
pooled tirzepatide arms
Source sentences
Summary
RCTs included in this study revealed that among 5800 patients, 78.22% (95% CI: 72.15% to 83.73%), 55.60% (95% CI: 46.54% to 64.47%), 32.28% (95% CI: 23.17% to 42.12%) achieved ≥5%, ≥10%, and ≥15% weight loss, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379601
02HumanSystematic reviewEfficacy outcome
In patients with overweight or obesity, a pooled single-arm analysis of tirzepatide trials found that 55.60% achieved weight loss of 10% or more.
In plain wordsIn pooled trials in people with overweight or obesity, 55.60% on tirzepatide lost at least 10% of body weight.
Peptide
Tirzepatide
Outcome
Not applicableProportion achieving at least 10% weight loss
Study
n = 5,800
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Proportion with 10% or more weight loss
55.6%
pooled tirzepatide arms
Source sentences
Summary
RCTs included in this study revealed that among 5800 patients, 78.22% (95% CI: 72.15% to 83.73%), 55.60% (95% CI: 46.54% to 64.47%), 32.28% (95% CI: 23.17% to 42.12%) achieved ≥5%, ≥10%, and ≥15% weight loss, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379602
03HumanSystematic reviewEfficacy outcome
In patients with overweight or obesity, a pooled single-arm analysis of tirzepatide trials found that 32.28% achieved weight loss of 15% or more.
In plain wordsIn pooled trials in people with overweight or obesity, 32.28% on tirzepatide lost at least 15% of body weight.
Peptide
Tirzepatide
Outcome
Not applicableProportion achieving at least 15% weight loss
Study
n = 5,800
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Proportion with 15% or more weight loss
32.28%
pooled tirzepatide arms
Source sentences
Summary
RCTs included in this study revealed that among 5800 patients, 78.22% (95% CI: 72.15% to 83.73%), 55.60% (95% CI: 46.54% to 64.47%), 32.28% (95% CI: 23.17% to 42.12%) achieved ≥5%, ≥10%, and ≥15% weight loss, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379603
04HumanSystematic reviewEfficacy outcome
In patients with overweight or obesity, tirzepatide 5 mg lowered body weight more than semaglutide (mean difference -1.90 kg).
In plain wordsIn people with overweight or obesity, tirzepatide 5 mg led to more weight loss than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseWeight change versus semaglutide, tirzepatide 5 mg
Study
n = 1,409
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Measurements
Mean difference in weight
−1.9 kg
tirzepatide 5 mg vs semaglutide
Source sentences
Summary
Tirzepatide 5 mg demonstrated weight loss superiority relative to placebo (MD: -12.47 kg, 95% CI: -13.94 kg to -11.00 kg) and semaglutide (n = 1409, MD: -1.90 kg, 95% CI: -2.97 kg to -0.83 kg) with dose-dependent increase for 10 mg and 15 mg doses.
2 context sentences(design, population, supporting numbers)
Summary · context
The comparison between tirzepatide and semaglutide was examined in the SURPASS-2 trial that was included in this systematic review.
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379605
05HumanSystematic reviewEfficacy outcome
In patients with overweight or obesity, tirzepatide 5 mg lowered body weight more than placebo (mean difference -12.47 kg).
In plain wordsIn people with overweight or obesity, tirzepatide 5 mg led to more weight loss than placebo.
Peptide
Tirzepatide
Outcome
DecreaseWeight change versus placebo, tirzepatide 5 mg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mgAs given in this study (human).
Measurements
Mean difference in weight
−12.47 kg
tirzepatide 5 mg vs placebo
Source sentences
Summary
Tirzepatide 5 mg demonstrated weight loss superiority relative to placebo (MD: -12.47 kg, 95% CI: -13.94 kg to -11.00 kg) and semaglutide (n = 1409, MD: -1.90 kg, 95% CI: -2.97 kg to -0.83 kg) with dose-dependent increase for 10 mg and 15 mg doses.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379604
06HumanSystematic reviewEfficacy outcome
In patients with overweight or obesity, the weight loss advantage of tirzepatide increased with dose at 10 mg and 15 mg.
In plain wordsIn people with overweight or obesity, higher tirzepatide doses (10 mg and 15 mg) gave greater weight loss.
Peptide
Tirzepatide
Outcome
DecreaseDose dependence of weight loss, 10 mg and 15 mg
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
10 mg and 15 mgAs given in this study (human).
Source sentences
Summary
with dose-dependent increase for 10 mg and 15 mg doses.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379606
07HumanSystematic reviewSafety outcome
In patients with overweight or obesity, tirzepatide increased the odds of gastrointestinal adverse events compared with placebo.
In plain wordsIn people with overweight or obesity, tirzepatide caused more stomach and gut side effects than placebo.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal adverse events versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
For AEs, there was increase odds of experiencing gastrointestinal AEs with tirzepatide compared to placebo, but no significant difference with semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379607
08HumanSystematic reviewSafety outcome
In patients with overweight or obesity, tirzepatide and semaglutide did not differ significantly in gastrointestinal adverse events.
In plain wordsIn people with overweight or obesity, tirzepatide and semaglutide did not differ significantly in stomach and gut side effects.
Peptide
Tirzepatide
Outcome
No significant changeGastrointestinal adverse events versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
but no significant difference with semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
Medline, Embase and Cochrane CENTRAL were searched for randomized controlled trials (RCTs) on tirzepatide's weight loss efficacy for these patients.
Report a problemFND-3725379608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT06745128

Tirzepatide for Obesity and Meth Use Disorder

University of Texas Southwestern Medical Centern = 353 Feb 2025 to 12 Feb 2026

Obesity · Methamphetamine Use Disorder

Trial page ClinicalTrials.govUpdated 28 Sept 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC